In summary, we designed a peptide conjugate vaccine targeting interleukin 17 receptor B which generated potent and specific polyclonal antibodies that were able to replicate therapeutic effects like its mAb counterpart, validating the concept that of a B-cell cancer vaccine as an efficacious and economic alternative to mAbs in cancer therapy. This evidence concerns the gene IL17RB and cancer.